GF60973791
Platinum
tube, 200mm, outside diameter 1.0mm, inside diameter 0.8mm, wall thickness 0.1mm, as drawn, 99.95%
Synonym(s):
Platinum, PT007200
Sign Into View Organizational & Contract Pricing
All Photos(2)
About This Item
Empirical Formula (Hill Notation):
Pt
CAS Number:
Molecular Weight:
195.08
MDL number:
UNSPSC Code:
12141734
PubChem Substance ID:
NACRES:
NA.23
Assay
99.95%
form
tubes
manufacturer/tradename
Goodfellow 609-737-91
resistivity
10.6 μΩ-cm, 20°C
L × wall thickness
200 mm × 0.1 mm
O.D. × I.D.
2.4 mm × 0.8 mm
bp
3827 °C (lit.)
mp
1772 °C (lit.)
density
21.45 g/cm3 (lit.)
SMILES string
[Pt]
InChI
1S/Pt
InChI key
BASFCYQUMIYNBI-UHFFFAOYSA-N
General description
For updated SDS information please visit www.goodfellow.com.
Legal Information
Product of Goodfellow
Storage Class Code
13 - Non Combustible Solids
WGK
nwg
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Fausto Petrelli et al.
Lung cancer (Amsterdam, Netherlands), 81(3), 337-342 (2013-07-31)
The sole agents pemetrexed (PEM), docetaxel and anti-EGFR agents are approved second-line therapies for non-small cell lung cancer (NSCLC) after failure with cisplatin-based doublets. The potential usefulness of platinum-based doublets as rechallenge for second-line chemotherapy has not yet been established.
Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer.
Himashinie V K Diyabalanage et al.
Cancer letters, 329(1), 1-8 (2012-10-04)
One of the most promising strategies to increase the efficacy of standard chemotherapy drugs is by combining them with low doses of histone deacetylases inhibitors (HDACis). Regarded as chemosensitizers, the addition of well-tolerated doses of HDACis to platinum-based chemotherapeutics has
Thorsten Langer et al.
Trends in pharmacological sciences, 34(8), 458-469 (2013-06-19)
Childhood cancer survival rates are now nearly 80% in more developed European countries because of improved therapies and better supportive care. Platinum chemotherapy drugs, such as cisplatin and carboplatin, are the cornerstone of many effective therapeutic protocols for childhood cancer.
Nicoletta Colombo
Future oncology (London, England), 9(12 Suppl), 19-23 (2013-11-15)
Ovarian cancer is the leading cause of gynecological cancer deaths worldwide. Despite primary treatment with platinum-containing regimens, the majority of women will experience recurrent disease and subsequent death. Recurrent ovarian cancer remains a challenge for successful management, and the choice
Antonio González
Future oncology (London, England), 9(12 Suppl), 29-35 (2013-11-15)
Ovarian carcinoma is still one of the most common causes of death from cancer in the western world. Despite high sensitivity to chemotherapy, the majority of patients will relapse within 3 years. In this article the focus is centered on
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service